West Pharmaceutical Services (WST) Operating Leases (2019 - 2026)

West Pharmaceutical Services (WST) has reported Operating Leases for 8 consecutive years, with $109.2 million the latest figure, recorded in Q2 2026.

• Quarterly Operating Leases rose 8.44% year-over-year to $109.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $109.2 million (up 8.44% YoY) and the FY2025 annual result came in at $95.6 million, up 16.87% from the prior year.
• Operating Leases retreated to $109.2 million in Q2 2026 per WST's latest filing, from $113.4 million in the prior quarter.
• Over the last five years, Operating Leases for WST reached as high as $113.4 million in Q1 2026 and fell as low as $78.7 million in Q1 2022.
• A 5-year average of $96.7 million and a median of $99.9 million in 2023 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2022 — Operating Leases soared 47.62% — and 2023, when it retreated 9.14%.
• Year by year, Operating Leases stood at $93.0 million in 2022, then decreased by 9.14% to $84.5 million in 2023, then retreated by 3.2% to $81.8 million in 2024, then increased by 16.87% to $95.6 million in 2025, then increased by 14.23% to $109.2 million in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $109.2 million, $113.4 million, and $95.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.